132 related articles for article (PubMed ID: 37580112)
1. Low risk of embryonic and other cancers in PIK3CA-related overgrowth spectrum: Impact on screening recommendations.
Faivre L; Crépin JC; Réda M; Nambot S; Carmignac V; Abadie C; Mirault T; Faure-Conter C; Mazereeuw-Hautier J; Maza A; Puzenat E; Collonge-Rame MA; Bursztejn AC; Philippe C; Thauvin-Robinet C; Chevarin M; Abasq-Thomas C; Amiel J; Arpin S; Barbarot S; Baujat G; Bessis D; Bourrat E; Boute O; Chassaing N; Coubes C; Demeer B; Edery P; El Chehadeh S; Goldenberg A; Hadj-Rabia S; Haye D; Isidor B; Jacquemont ML; Van Kien PK; Lacombe D; Lehalle D; Lambert L; Martin L; Maruani A; Morice-Picard F; Petit F; Phan A; Pinson L; Rossi M; Touraine R; Vanlerberghe C; Vincent M; Vincent-Delorme C; Whalen S; Willems M; Marle N; Verkarre V; Devalland C; Devouassoux-Shisheboran M; Abad M; Rioux-Leclercq N; Bonniaud B; Duffourd Y; Martel J; Binquet C; Kuentz P; Vabres P
Clin Genet; 2023 Nov; 104(5):554-563. PubMed ID: 37580112
[TBL] [Abstract][Full Text] [Related]
2. Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation.
Gripp KW; Baker L; Kandula V; Conard K; Scavina M; Napoli JA; Griffin GC; Thacker M; Knox RG; Clark GR; Parker VE; Semple R; Mirzaa G; Keppler-Noreuil KM
Am J Med Genet A; 2016 Oct; 170(10):2559-69. PubMed ID: 27191687
[TBL] [Abstract][Full Text] [Related]
3. Urine cell-free DNA is a biomarker for nephroblastomatosis or Wilms tumor in PIK3CA-related overgrowth spectrum (PROS).
Biderman Waberski M; Lindhurst M; Keppler-Noreuil KM; Sapp JC; Baker L; Gripp KW; Adams DM; Biesecker LG
Genet Med; 2018 Sep; 20(9):1077-1081. PubMed ID: 29300373
[TBL] [Abstract][Full Text] [Related]
4. Undergrowth Of First Toe In PiK3CA-Related Overgrowth Spectrum (PROS).
Triana P; Sarmiento MDC; Rodriguez-Laguna L; Martinez-Glez V; Lopez-Gutierrez JC
Ann Vasc Surg; 2023 Jan; 88():233-238. PubMed ID: 35878698
[TBL] [Abstract][Full Text] [Related]
5. Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing.
Kuentz P; St-Onge J; Duffourd Y; Courcet JB; Carmignac V; Jouan T; Sorlin A; Abasq-Thomas C; Albuisson J; Amiel J; Amram D; Arpin S; Attie-Bitach T; Bahi-Buisson N; Barbarot S; Baujat G; Bessis D; Boccara O; Bonnière M; Boute O; Bursztejn AC; Chiaverini C; Cormier-Daire V; Coubes C; Delobel B; Edery P; Chehadeh SE; Francannet C; Geneviève D; Goldenberg A; Haye D; Isidor B; Jacquemont ML; Khau Van Kien P; Lacombe D; Martin L; Martinovic J; Maruani A; Mathieu-Dramard M; Mazereeuw-Hautier J; Michot C; Mignot C; Miquel J; Morice-Picard F; Petit F; Phan A; Rossi M; Touraine R; Verloes A; Vincent M; Vincent-Delorme C; Whalen S; Willems M; Marle N; Lehalle D; Thevenon J; Thauvin-Robinet C; Hadj-Rabia S; Faivre L; Vabres P; Rivière JB
Genet Med; 2017 Sep; 19(9):989-997. PubMed ID: 28151489
[TBL] [Abstract][Full Text] [Related]
6. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Keppler-Noreuil KM; Rios JJ; Parker VE; Semple RK; Lindhurst MJ; Sapp JC; Alomari A; Ezaki M; Dobyns W; Biesecker LG
Am J Med Genet A; 2015 Feb; 167A(2):287-95. PubMed ID: 25557259
[TBL] [Abstract][Full Text] [Related]
8. [PIK3CA-related overgrowth syndrome (PROS)].
Venot Q; Canaud G
Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
[TBL] [Abstract][Full Text] [Related]
9. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
10. Cancer-Associated PIK3CA Mutations in Overgrowth Disorders.
Madsen RR; Vanhaesebroeck B; Semple RK
Trends Mol Med; 2018 Oct; 24(10):856-870. PubMed ID: 30197175
[TBL] [Abstract][Full Text] [Related]
11. Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome.
Keppler-Noreuil KM; Lozier J; Oden N; Taneja A; Burton-Akright J; Sapp JC; Biesecker LG
Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):571-581. PubMed ID: 31490637
[TBL] [Abstract][Full Text] [Related]
12. Utility of clinical high-depth next generation sequencing for somatic variant detection in the PIK3CA-related overgrowth spectrum.
Hucthagowder V; Shenoy A; Corliss M; Vigh-Conrad KA; Storer C; Grange DK; Cottrell CE
Clin Genet; 2017 Jan; 91(1):79-85. PubMed ID: 27307077
[TBL] [Abstract][Full Text] [Related]
13. Activating PIK3CA postzygotic mutations in segmental overgrowth of muscles with bone involvement in the body extremities.
Tian W; Sun L; Zhang Q; Zhao J; Guo Y; Zhong W; Liu L; Meirelles K; Tang S; Zhang J; Huang Y; Yin Y; Zhang N; Zhao Z; Li Q; Wu N; Fang P; Chang F; Wu Z
Mol Genet Genomics; 2022 Mar; 297(2):387-396. PubMed ID: 35122151
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of the disorders of the Pik3ca-related overgrowth spectrum (Pros).
Reynolds G; Cardaropoli S; Carli D; Luca M; Gazzin A; Coppo P; La Selva R; Piglionica M; Bagnulo R; Turchiano A; Ranieri C; Resta N; Mussa A
Eur J Hum Genet; 2023 Nov; 31(11):1333-1336. PubMed ID: 37365400
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic and molecular characterization of five patients with PIK3CA-related overgrowth spectrum (PROS).
Gökpınar İli E; Taşdelen E; Durmaz CD; Altıner Ş; Tuncalı T; Martinez-Glez V; Karabulut HG; Vural S; Ceylaner S; Acar MO; Ilgın Ruhi H
Am J Med Genet A; 2022 Jun; 188(6):1792-1800. PubMed ID: 35238469
[TBL] [Abstract][Full Text] [Related]
16.
Pagliazzi A; Oranges T; Traficante G; Trapani C; Facchini F; Martin A; Semeraro A; Perrone A; Filippeschi C; Giglio S
Front Pediatr; 2021; 9():732836. PubMed ID: 34568242
[No Abstract] [Full Text] [Related]
17. Genotypes and phenotypes heterogeneity in PIK3CA-related overgrowth spectrum and overlapping conditions: 150 novel patients and systematic review of 1007 patients with PIK3CA pathogenetic variants.
Mussa A; Leoni C; Iacoviello M; Carli D; Ranieri C; Pantaleo A; Buonuomo PS; Bagnulo R; Ferrero GB; Bartuli A; Melis D; Maitz S; Loconte DC; Turchiano A; Piglionica M; De Luisi A; Susca FC; Bukvic N; Forleo C; Selicorni A; Zampino G; Onesimo R; Cappuccio G; Garavelli L; Novelli C; Memo L; Morando C; Della Monica M; Accadia M; Capurso M; Piscopo C; Cereda A; Di Giacomo MC; Saletti V; Spinelli AM; Lastella P; Tenconi R; Dvorakova V; Irvine AD; Resta N
J Med Genet; 2023 Feb; 60(2):163-173. PubMed ID: 35256403
[TBL] [Abstract][Full Text] [Related]
18. Causal somatic mutations in urine DNA from persons with the CLOVES subgroup of the PIK3CA-related overgrowth spectrum.
Michel ME; Konczyk DJ; Yeung KS; Murillo R; Vivero MP; Hall AM; Zurakowski D; Adams D; Gupta A; Huang AY; Chung BHY; Warman ML
Clin Genet; 2018 May; 93(5):1075-1080. PubMed ID: 29231959
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA vascular overgrowth syndromes: an update.
Hughes M; Hao M; Luu M
Curr Opin Pediatr; 2020 Aug; 32(4):539-546. PubMed ID: 32692051
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum.
Parker VER; Keppler-Noreuil KM; Faivre L; Luu M; Oden NL; De Silva L; Sapp JC; Andrews K; Bardou M; Chen KY; Darling TN; Gautier E; Goldspiel BR; Hadj-Rabia S; Harris J; Kounidas G; Kumar P; Lindhurst MJ; Loffroy R; Martin L; Phan A; Rother KI; Widemann BC; Wolters PL; Coubes C; Pinson L; Willems M; Vincent-Delorme C; ; Vabres P; Semple RK; Biesecker LG
Genet Med; 2019 May; 21(5):1189-1198. PubMed ID: 30270358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
